Search Results
Standard treatment of elderly patients with AML & evaluating IDH inhibitors in younger patients
Is remission the same in younger or older patients with AML?
Treatment approaches for elderly/unfit patients with AML ineligible for intensive chemotherapy
Managing Treatment for IDH2-Mutated AML
Treating older patients with AML in 2020: What is new and promising?
Management of Older Patients with AML
The importance of geriatric assessment and patient selection for SCT in AML
Can Venetoclax plus Azacitidine Help AML Patients Ineligible for Intensive Treatment?
An insight into MRD monitoring and MRD-driven treatment in AML
The possibility of using MRD status to drive treatment in AML
The efficacy and toxicity of reduced venetoclax exposure in patients with treatment-naïve AML
Oral Combo for Newly Diagnosed Older Adults with Acute Myeloid Leukemia | Gabriel Mannis | ASH 2021
